Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva, a company that produces, develops and markets affordable generic drugs as well as specialty pharmaceuticals and active pharmaceutical ingredients, has reported net sales of $4.25bn for the third quarter ended 30 September 2010, an increase of 20%, compared to $3.55bn for the same period in 2009.
Subscribe to our email newsletter
Teva posted a net income of $1.05bn for the third quarter 2010, or $1.15 per diluted share, compared to $649m, or $0.72 per diluted share, for the comparable period in 2009.
Teva’s operating income was $1.19bn, compared to $753m for the comparable period in 2009.
For the nine months ended 30 September 2010, Teva posted net sales of $11.7bn, compared to $10.1bn for the year ago period.
Teva has reported operating income of $3.01bn for the nine months ended 30 September 2010, compared to $1.99bn for the year ago period.
Teva president and CEO Shlomo Yanai said that this was another outstanding quarter of profitable growth for Teva, with record-breaking sales across all the geographies and major businesses, leading to record-breaking results across the board.
"This was also a quarter of major strategic achievements and operational successes, particularly in the US with high growth rates in our generics business, and in Europe, where we closed our acquisition of ratiopharm and are already making excellent progress on the integration–which we now expect to complete ahead of schedule," Yanai said.